drugset
drugset / Trial / NCT06789159

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

NCT06789159 ↗

Phase 1 Recruiting 30 enrolled Pierluigi Porcu National Cancer Institute (NCI) · collabThe Wistar Institute · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using daily oral dosing of VK-2019 in three dose escalation cohorts: 600 mg/day, 1200 mg/day, 1800 mg/day for 28 days (cycle), until progression or toxicity.

Timeline

Start
2026-08
Primary completion
2028-10-01
Completion
2028-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject VK-2019 Small molecule 600 mg Oral
Subject VK-2019 Small molecule 1200 mg Oral
Subject VK-2019 Small molecule 1800 mg Oral

Indications

Epstein-Barr virus infection diffuse large B-cell lymphoma